SCHEMBL844946

SCHEMBL844946

NC(=O)C(CCC(=O)O)N1Cc2ccccc2C1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 4/20 0.59
MAPT P10636 3/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 4/20 0.57
TSHR P16473 2/20 0.53
SIRT1 Q96EB6 1/20 0.53
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 2/20 0.52
XIAP P98170 1/20 0.52
HKDC1 Q2TB90 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
TP53 P04637 1/20 0.51
GLA P06280 1/20 0.51
POLB P06746 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29774638 0.89 ALOX15 (0.70) ALOX15MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL824555 0.89 ALOX15 (0.70) ALOX15MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL845435 0.84 ALOX15 (0.67) ALOX15MAPTSMN1; SMN2KDM4ETSHR
Potassium SCHEMBL30798831 0.84 NPC1 (0.54) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL27173134 0.84 MEN1 (0.48) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL27172845 0.84 MEN1 (0.48) ALOX15MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL27204924 0.84 MEN1 (0.48) ALOX15MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL12942069 0.83 ALOX15 (0.54) ALOX15MAPTSMN1; SMN2KDM4ETSHR
SCHEMBL825646 0.83 MAPT (0.80) ALOX15MAPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL23704744 0.83 ALOX15 (0.43) ALOX15MAPTSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2024-07-25 US claimed
CN-114113294-B Online measuring device and method for determining yield strength and tensile strength of strip steel 宝山钢铁股份有限公司 2023-12-12 CN claimed
CN-114113294-A Online measuring device and method for determining yield strength and tensile strength of strip steel 宝山钢铁股份有限公司 2022-03-01 CN claimed
US-20260150491-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2026-05-28 US disclosed
EP-4750286-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT Canon Kabushiki Kaisha (JP) 2026-05-27 EP disclosed
CN-122079730-A Organic compound and organic light-emitting element 2026-05-26 CN disclosed
CN-122055591-A Docking station for a spectrometer and associated measurement method 法国原子能源和替代能源委员会 2026-05-15 CN disclosed
US-20260136815-A1 LIGHT EMITTING DEVICE, DISPLAY DEVICE, PHOTOELECTRIC CONVERSION DEVICE, ELECTRONIC APPARATUS, ILLUMINATION DEVICE, MOVING BODY, AND WEARABLE DEVICE CANON KK (JP) 2026-05-14 US disclosed
EP-4742869-A1 LIGHT EMITTING DEVICE, DISPLAY DEVICE, PHOTOELECTRIC CONVERSION DEVICE, ELECTRONIC APPARATUS, ILLUMINATION DEVICE, MOVING BODY, AND WEARABLE DEVICE Canon Kabushiki Kaisha (JP) 2026-05-13 EP disclosed
CN-122028624-A Light emitting device, display device, photoelectric conversion device, electronic apparatus, lighting device, mobile body, and wearable device 佳能株式会社 2026-05-12 CN disclosed
US-20260090255-A1 LIGHT EMITTING DEVICE, DISPLAY DEVICE, PHOTOELECTRIC CONVERSION DEVICE, ELECTRONIC APPARATUS, ILLUMINATION DEVICE, MOVING BODY, AND WEARABLE DEVICE CANON KK (JP) 2026-03-26 US disclosed
US-11251375-B2 While organic EL element CANON KABUSHIKI KAISHA (JP) 2022-02-15 US disclosed
US-20200377512-A1 SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2020-12-03 US disclosed
WO-2020243379-A1 SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CELGENE CORPORATION (US) 2020-12-03 WO disclosed
US-8143283-B1 Methods for treating blood-born tumors with thalidomide THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2012-03-27 US disclosed
US-7723361-B2 Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide CELGENE CORPORATION (US) 2010-05-25 US disclosed
EP-1920773-A1 Compositions for inhibition of anglogenesis The Children's Medical Center Corporation (US) 2008-05-14 EP disclosed
US-20080096952-A1 Methods for the treatment of atherosclerosis, using substituted phenethylsulfones CELGENE CORPORATION 2008-04-24 US disclosed
US-20080096952-A1 Methods for the treatment of atherosclerosis, using substituted phenethylsulfones CELGENE CORPORATION 2008-04-24 US disclosed
CN-1342146-A Substituted 1-oxo-and 1, 3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels CELGENE CORP (US) 2002-03-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377512-A1 SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH CPT1A, GOT2, IDH2 ALOX15 2551/4885MAPT 1392/4885SMN1; SMN2 474/4885
US-20260150491-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT NR2E3, RORB, RORA ALOX15 1527/4885MAPT 3519/4885SMN1; SMN2 2513/4885
US-20260136815-A1 LIGHT EMITTING DEVICE, DISPLAY DEVICE, PHOTOELECTRIC CONVERSION DEVICE, ELECTRONIC APPARATUS, ILLUMINATION DEVICE, MOVING BODY, AND WEARABLE DEVICE L1CAM, LAGE3, EPHA4 ALOX15 4171/4885MAPT 2330/4885SMN1; SMN2 1107/4885
US-20260090255-A1 LIGHT EMITTING DEVICE, DISPLAY DEVICE, PHOTOELECTRIC CONVERSION DEVICE, ELECTRONIC APPARATUS, ILLUMINATION DEVICE, MOVING BODY, AND WEARABLE DEVICE L1CAM, DSP, LAGE3 ALOX15 3755/4885MAPT 2006/4885SMN1; SMN2 1055/4885
US-20080096952-A1 Methods for the treatment of atherosclerosis, using substituted phenethylsulfones TNF, TGFB1, TGFB2 ALOX15 2059/4885MAPT 3273/4885SMN1; SMN2 3759/4885
US-20240251664-A1 LIGHT EMITTING ELEMENT AND AMINE COMPOUND FOR THE SAME NES, NFE2L2, NUCB2 ALOX15 2129/4885MAPT 1850/4885SMN1; SMN2 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.